Heart Failure Therapy at Emory

As one of the premier academic heart failure programs in the world, Emory’s Heart Failure Therapy program is committed to the advancement of the heart failure therapy and improvement of patient outcomes. Every day, we lead heart failure research efforts; educate physicians, staff, patients and their families; and treat heart failure patients with compassionate and comprehensive care.

Emory Facts:

  • Emory University’s Heart Failure Therapy and Transplantation program was selected as one of nine members of the Heart Failure Clinical Research Network (HFCRN) by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). Emory has received a seven-year, $2.5 million grant to develop clinical trials in heart failure and additional funding over time to carry out these trials. The HFCRN is a cooperative network of advanced heart failure clinical and research centers. HFCRN is charged with accelerating innovative research and developing strategies to diagnose, manage and treat all forms of heart failure. 
  • Emory’s cardiac surgeons implanted Georgia’s first ventricular assist device (VAD) as a form of destination therapy in 2006.
  • Emory University Hospital’s VAD Program earned the Joint Commission Gold Seal of Approval for Destination Therapy in 2009 and recertified in 2011.
  • Emory University Hospital is one of only a few hospitals in Georgia to be VAD-certified by The Joint Commission and one of fewer than 100 centers in the US. Joint Commission certification shows patients who need LVADs as destination therapy that Emory is a leader in the field with the best clinical practices.
  • Emory cardiologists have the most extensive base of clinical experience in evaluating and implanting biventricular pacemakers. Approximately 1,000 of these devices have been implanted in patients with heart failure at Emory Hospitals.
Patient Videos
Women's Heart Centerlearn more